Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective.
Renata Portella NunesFlávio Eduardo HiraiEduardo Buchelle RodriguesMichel Eid FarahPublished in: Arquivos brasileiros de oftalmologia (2020)
From the Brazilian SUS perspective, bevacizumab is more cost-effective than ranibizumab for the treatment of neovascular age-related macular degeneration. Its use could allow potential annual savings in health budget.